Microarray-based analysis of polynucleotide sequence variations
    2.
    发明授权
    Microarray-based analysis of polynucleotide sequence variations 失效
    基于芯片的多核苷酸序列变异分析

    公开(公告)号:US06376191B1

    公开(公告)日:2002-04-23

    申请号:US09707366

    申请日:2000-11-06

    CPC classification number: C12Q1/6858 C12Q2565/501 C12Q2565/537

    Abstract: Solid phase polymerase-mediated amplification approaches using immobilized primers on a microarray are provided for detecting sequence variations in a target polynucleotide. The methods and compositions provided herein are useful for research and clinical applications, particularly for large scale assays of genetic information in biological samples of interest.

    Abstract translation: 提供使用固定引物在微阵列上的固相聚合酶介导的扩增方法,用于检测靶多核苷酸中的序列变异。 本文提供的方法和组合物可用于研究和临床应用,特别是对于感兴趣的生物样品中遗传信息的大规模测定。

    Recombinant human albumin-interleukin-11 fusion protein with long-lasting biological effects
    4.
    发明授权
    Recombinant human albumin-interleukin-11 fusion protein with long-lasting biological effects 有权
    重组人白蛋白 - 白细胞介素-11融合蛋白具有持久的生物学效应

    公开(公告)号:US08084021B2

    公开(公告)日:2011-12-27

    申请号:US12203116

    申请日:2008-09-02

    Applicant: Zailin Yu Yan Fu

    Inventor: Zailin Yu Yan Fu

    Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

    Abstract translation: 提供了通过使用人血清白蛋白(HSA)和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物,试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽,并且优选地,当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中,可以改善体内生物活性分子的稳定性,并且由于体内毒性降低和持久的治疗效果,治疗指数增加。 此外,提供制造方法用于在酵母中有效,成本有效地生产这些重组蛋白。

    Recombinant human albumin fusion proteins with long-lasting biological effects
    5.
    发明授权
    Recombinant human albumin fusion proteins with long-lasting biological effects 有权
    重组人白蛋白融合蛋白具有持久的生物学效应

    公开(公告)号:US07244833B2

    公开(公告)日:2007-07-17

    申请号:US10609346

    申请日:2003-06-26

    Applicant: Zailin Yu Yan Fu

    Inventor: Zailin Yu Yan Fu

    Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

    Abstract translation: 提供了通过使用人血清白蛋白(HSA)和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物,试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽,并且优选地,当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中,可以改善体内生物活性分子的稳定性,并且由于体内毒性降低和持久的治疗效果,治疗指数增加。 此外,提供制造方法用于在酵母中有效,成本有效地生产这些重组蛋白。

    Recombinant Human Albumin-Interleukin-11 Fusion Protein With Long-Lasting Biological Effects
    8.
    发明申请
    Recombinant Human Albumin-Interleukin-11 Fusion Protein With Long-Lasting Biological Effects 有权
    重组人白细胞介素-11融合蛋白具有持久的生物学效应

    公开(公告)号:US20100068173A1

    公开(公告)日:2010-03-18

    申请号:US12203116

    申请日:2008-09-02

    Applicant: Zailin Yu Yan Fu

    Inventor: Zailin Yu Yan Fu

    Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

    Abstract translation: 提供了通过使用人血清白蛋白(HSA)和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物,试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽,并且优选地,当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中,可以改善体内生物活性分子的稳定性,并且由于体内毒性降低和持久的治疗效果,治疗指数增加。 此外,提供制造方法用于在酵母中有效,成本有效地生产这些重组蛋白。

    Recombinant human albumin fusion proteins with long-lasting biological effects
    9.
    发明申请
    Recombinant human albumin fusion proteins with long-lasting biological effects 有权
    重组人白蛋白融合蛋白具有持久的生物学效应

    公开(公告)号:US20080009446A1

    公开(公告)日:2008-01-10

    申请号:US11825686

    申请日:2007-07-08

    Applicant: Zailin Yu Yan Fu

    Inventor: Zailin Yu Yan Fu

    Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

    Abstract translation: 提供了通过使用人血清白蛋白(HSA)和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物,试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽,并且优选地,当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中,可以改善体内生物活性分子的稳定性,并且由于体内毒性降低和持久的治疗效果,治疗指数增加。 此外,提供制造方法用于在酵母中有效,成本有效地生产这些重组蛋白。

Patent Agency Ranking